ONO PHARMACEUTICAL CO.,LTD.

January 15, 2019

Array BioPharma Announces 15.3 Months Median Overall Survival from the Safety Lead-in of the Phase 3 BEACON CRC Trial of the Combination BRAFTOVI®, MEKTOVI® and ERBITUX® in *BRAF*-Mutant Metastatic Colorectal Cancer

This information is intended to notify the press release issued on January 14 (ET) by Array BioPharma Inc. Please click http://www.arraybiopharma.com/ for the original press release distributed by Array.

(1st paragraph of the press release)

Boulder, Colo. *(January 14, 2019)* – Array BioPharma Inc. (Nasdaq: ARRY) today announced updated safety and efficacy results, including mature overall survival (OS), from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of BRAFTOVI® (encorafenib), a BRAF inhibitor, MEKTOVI® (binimetinib), a MEK inhibitor and ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with *BRAF*^{V600E}-mutant metastatic colorectal cancer (mCRC). The results showed that mature median OS was 15.3 months (95% CI, 9.6–not reached) for patients treated with the triplet. These data will be presented on Saturday, January 19 at the ASCO 2019 Gastrointestinal Cancers Symposium in San Francisco, California.

About the Ono and Array BioPharma Collaboration

In May 2017, Ono Pharmaceutical Co., Ltd. (“ONO”) entered into the license agreement with Array BioPharma Inc. regarding BRAFTOVI® (encorafenib), a BRAF inhibitor and MEKTOVI® (binimetinib), a MEK inhibitor and received rights to develop and commercialize both products in Japan and South Korea.

In January 2019, ONO received the manufacturing and marketing approvals for both products in Japan for the indication of unresectable BRAF-mutant melanoma. The products are currently in two global Phase 3 clinical trials for the treatment of patients with BRAF-mutant melanoma (COLUMBUS study) and BRAF-mutant colorectal cancer (BEACON CRC study) as a combination therapy.

Contacts:
ONO PHARMACEUTICAL CO., LTD.
Corporate Communications
public_relations@ono.co.jp